美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Pharmacyclics

255.00

+0.10000.04%

成交量：29.91万

成交额：7,627.05万

市值：196.55亿

市盈率：277.17

高：255.95

开：255.16

低：254.45

收：254.90

52周最高：255.95

52周最低：254.45

股本：7,708.00万

流通股本：5,272.99万

量比：0.57

换手率：0.57%

股息：- -

股息率：- -

每股收益(TTM):0.9200

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

公司资料

公司名字：

Pharmacyclics

交易所：

NASDAQ

成立时间：

- -

员工人数：

- -

公司地址：

- -

官网：

http://www.pharmacyclics.com

邮编：

- -

电话：

- -

传真：

- -

简介：

Pharmacyclics的公司是一家生物制药公司，致力于开发和销售创新的小分子药物用于癌症和免疫介导的疾病的治疗。 Pharmacyclics的市场IMBRUVICA（ibrutinib），但有其他候选产品处于临床开发和优化铅的几个临床分子。IMBRUVICA是一个先入级，口服，每日一次治疗，抑制一种称为布鲁顿的酪氨酸激酶（BTK）蛋白。 IMBRUVICA正在联合开发和Pharmacyclics的和扬森生物技术公司及其附属公司（扬森），强生公司的杨森制药公司之一商品化。IMBRUVICA目前被批准用于在大约40个国家，包括美国，加拿大和欧盟范围内的28个国家（EU）的使用。

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/PCYC/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"PCYC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PCYC\",,,,,undefined,":{"symbol":"PCYC","market":"US","secType":"STK","nameCN":"Pharmacyclics","latestPrice":255,"timestamp":1431115200000,"preClose":254.9,"halted":0,"volume":299100,"delay":0,"changeRate":0.00039231071008236296,"floatShares":52729884,"shares":77080000,"eps":0.92,"marketStatus":"盘前交易","change":0.1,"latestTime":"02-24 04:57:38 EST","open":255.16,"high":255.95,"low":254.45,"amount":76270500,"amplitude":0.005885,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.92,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1771943400000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":255,"volumeRatio":0.574287},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"PCYC\",,,,,undefined,":{"symbol":"PCYC","floatShares":52729884,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.574287,"shares":77080000,"dividePrice":0,"high":255.95,"amplitude":0.005885,"preClose":254.9,"low":254.45,"week52Low":254.45,"pbRate":"--","week52High":255.95,"institutionHeld":0,"latestPrice":255,"eps":0.92,"divideRate":0,"volume":299100,"delay":0,"ttmEps":0.92,"open":255.16,"prevYearClose":255},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/PCYC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2015-05-01","symbol":"PCYC","fiscalQuarterEnding":null,"expectedEps":0.05,"name":null,"time":"","type":"earning","dateTimestamp":1430452800000,"reportTimeType":"","actualEps":0.13}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"PCYC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"PCYC\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.pharmacyclics.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0009},{"period":"1month","weight":-0.0099},{"period":"3month","weight":0.0109},{"period":"6month","weight":0.0553},{"period":"1year","weight":0.1374},{"period":"ytd","weight":0.0007}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Pharmacyclics的公司是一家生物制药公司，致力于开发和销售创新的小分子药物用于癌症和免疫介导的疾病的治疗。 Pharmacyclics的市场IMBRUVICA（ibrutinib），但有其他候选产品处于临床开发和优化铅的几个临床分子。IMBRUVICA是一个先入级，口服，每日一次治疗，抑制一种称为布鲁顿的酪氨酸激酶（BTK）蛋白。 IMBRUVICA正在联合开发和Pharmacyclics的和扬森生物技术公司及其附属公司（扬森），强生公司的杨森制药公司之一商品化。IMBRUVICA目前被批准用于在大约40个国家，包括美国，加拿大和欧盟范围内的28个国家（EU）的使用。","exchange":"NASDAQ","name":"Pharmacyclics","nameEN":"Pharmacyclics, Inc."}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"PCYC\",market:\"US\",,,undefined,":null}}